Primaxin

Pays: Nouvelle-Zélande

Langue: anglais

Source: Medsafe (Medicines Safety Authority)

Ingrédients actifs:

Cilastatin sodium 571mg equivalent to to 500 mg cilastatin acid. Includes 4.6% overage.; Imipenem monohydrate 560mg equivalent to to 500 mg imipenem. Includes 4.6% overage.

Disponible depuis:

Merck Sharp & Dohme (New Zealand) Limited

DCI (Dénomination commune internationale):

Cilastatin sodium 571 mg (Equiv. to 500 mg cilastatin acid. Includes 4.6% overage.)

forme pharmaceutique:

Powder for injection

Composition:

Active: Cilastatin sodium 571mg equivalent to to 500 mg cilastatin acid. Includes 4.6% overage. Imipenem monohydrate 560mg equivalent to to 500 mg imipenem. Includes 4.6% overage. Excipient: Sodium bicarbonate

Unités en paquet:

Ampoule, glass, 5x13ml (Monovial), 5 dose units

classe:

Prescription

Type d'ordonnance:

Prescription

Fabriqué par:

Merck Sharp & Dohme Corp

Descriptif du produit:

Package - Contents - Shelf Life: Ampoule, glass, 5x13ml (Monovial) - 5 dose units - 24 months from date of manufacture stored at or below 25°C 4 hours reconstituted stored at or below 25°C 24 hours reconstituted stored at 2° to 8°C (Refrigerate, do not freeze)

Date de l'autorisation:

1996-03-20